PORTSMOUTH, NH, 17 March 2021 / PRNewswire / – Epredia, a global leader in precision cancer diagnosis, and Paige, a global leader in AI-based diagnostic software in pathology, today announced that they have signed a commercial distribution agreement for a comprehensive portfolio of Paige diagnostic software solutions.
Under the terms of this agreement, Epredia has been appointed as the global distribution partner of Paige’s entire portfolio of imaging diagnostic solutions. In addition, Epredia will have exclusive distribution rights on Japan. In the second quarter of 2021, Epredia will start commercializing the Paige solution together with Epredia’s existing products. United States of America and the major European powers, further strengthening its comprehensive digital pathology portfolio which includes the best-in-class CE-marked 3DHistech P1000 scanner *.
The Paige portfolio includes the Paige Platform, a comprehensive imaging solution consisting of a fast trackless footprint viewer, storage capabilities and AI-based diagnostic software to help pathologists review cases and support their overall workflow.
The FDA approved and CE marked Paige platform features FullFocus ™, an intuitive and responsive viewer for pathology scanning that supports primary diagnosis and its Data Management solution for pathology scan storage. The Paige platform is designed to be compatible with existing pathology solutions, including most laboratory scanners, monitors and information systems.
Paige’s AI-based diagnostic software solution is designed to increase the number of cases that can be reviewed and with greater confidence and accuracy. Currently Paige Prostate and Paige Breast are CE marked and available for outside clinical use United States of America. Paige Prostate RUO and Paige Breast RUO are research use-only solutions available at United States of America.
“We are very excited to enter into this partnership with Paige to commercialize its highly innovative portfolio of AI-based digital pathology solutions,” he explained. John Marotta, President, Epredia and Chief Executive Officer, PHC Holdings Corporation. “We believe that digital pathology is an important part of future cancer diagnosis that can greatly improve patient care. We see enormous potential in Paige’s portfolio and believe that it complements our portfolio perfectly. This deal provides us with access to a portfolio that is diverse. highly innovative products that enable us to realize our mission to improve lives by improving cancer diagnostics for patients. “
“This commercial partnership with Epredia is an exciting step for Paige and we are delighted to be working with one of the leading companies in the field of anatomical pathology. Epredia’s extensive global commercial reach will support our efforts to expand our geographic footprint,” said Epredia. Leo Grady, Ph.D., Executive Director of Paige. “Our goal is to transform the diagnostic space by offering a portfolio of software applications that help optimize patient outcomes by enabling pathologists to unlock insights from each sample and return results to doctors and patients more quickly. This commercial agreement will help put our solutions into more hands. pathologists around the world to help patients get the most timely and effective treatment. “
* Regulatory requirements for the 3DHistech P1000 scanner vary by country, please contact your commercial partner to confirm use of an approved scanner in your country.
Epredia is a global leader in the field of anatomical pathology, providing comprehensive solutions for precision cancer diagnosis and tissue diagnostics. Supported by major brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, the Epredia portfolio includes microscope slides, instruments and consumables. Epredia was founded following the acquisition of the Pathology Anatomical Pathology business by PHC Holdings by PHC Holdings in 2019. Epredia has its main site at United States of America, that great Britain, German, Switzerland and China with a total of about 1,200 employees. Epredia is committed to achieving its mission of improving lives by improving cancer diagnostics for patients worldwide. For more information about Epredia and its products, please visit www.epredia.com.
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from the Memorial Sloan Kettering Cancer Center (MSK). The company makes computational pathology products designed so that patients and their care teams can make effective and more informed treatment decisions. With a new class of AI-based technology positioned to drive the future of diagnostics, Paige created a platform to bring this new technology to pathologists to transform their workflows and increase diagnostic confidence and productivity. Paige’s products provide pathologists and oncologists with insights so that they can arrive efficiently at a more precise diagnosis for a patient. Paige is the first company to receive an FDA breakthrough designation for a computational pathology product.